Confo Therapeutics Nominates SSTR5 Agonist Antibody CFTX-2034 as Development Candidate for Post-Bariatric Hypoglycemia [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Ghent, Belgium – December 18, 2025 – Confo Therapeutics , a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has selected CFTX-2034 an SSTR5 agonist, as its new antibody drug candidate, designed to treat conditions linked to hyperinsulinemic hypoglycemia, specifically Post-Bariatric Hypoglycemia (PBH). The company is now advancing CFTX-2034 through IND-enabling studies and towards the clinic, marking an important advance in its pipeline of novel GPCR-targeting therapeutics for metabolic and endocrine diseases. CFTX-2034 is a major milestone for the company as it is its first agonistic antibody development candidate. This builds on Confo's proven track record in discovering and developing highly differentiated drug candidates, with its first program, CFTX-1554, successfully out-licensed to Eli Lilly and Company in 2023. Cedric Ververken, CEO of Confo Therapeutics, stated: “Since committing to the metabolic and endocrin
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Jim Cramer Discusses Major Catalyst For Eli Lilly (LLY) [Yahoo! Finance]Yahoo! Finance
- FlyteHealth to Expand Direct Access to Obesity Management Medication for Employers [Yahoo! Finance]Yahoo! Finance
- Ovarian cancer survivor on finding hope through cancer clinical trials [CBS News]CBS News
- BofA Maintains Buy on Eli Lilly (LLY), Expects 2027 Earnings to Fully Realize Value of Obesity Drug Launches [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (LLY) Announces Updated Meaningful Data on Breast Cancer Treatment [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 10/30/25 - Beat
LLY
Sec Filings
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- LLY's page on the SEC website